Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced today that the U.S. Food and Drug Administration (FDA) approved REXULTI® (brexpiprazole) as an adjunctive therapy for the treatment of adults with major depressive disorder (MDD) and as a treatment for adults with schizophrenia.
REXULTI was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become available to patients in the U.S. in early August 2015.
“One key priority for physicians is to find medications that help improve symptoms and are tolerable for patients”
I’m on abilify, and if this is easier to tolerate I’d take it. I’m going to wait a while (2 years?) just to make sure there’s nothing horribly wrong with it.
I think that’s a very good idea, because this drug has a mechanism of action that seem to me far more like an anti-D than an anti-P. Personally, I am waiting to see what the great Stephen Stahl has to say about it (see https://stahlonline.cambridge.org/aboutus.jsf) as he has been the single most respected name in the basic education on psychopharmacology over the past 15 years or so.
